/s/ Joseph B. Armes, /s/ Joseph B. Armes ; Name:, Joseph B. Armes ; Title:, Chairman of the Board,
GENIE ENERGY LTD., GENIE ENERGY LTD. ; By:, /s/ Michael Stein ; Name:, Michael Stein ; Title:, Chief Executive Officer
Additional Information and Where to Find It · In connection with the proposed transaction between GE and Baker Hughes, the new NYSE listed corporation (“Newco”) will prepare and file with the SEC a registration statement on Form S-4 that will include a combined proxy statement/prospectus of Newco and Baker Hughes (the “Combined Proxy Statement/Prospectus”). Baker Hughes and Newco will prepare and file the Combined Proxy Statement/Prospectus with the SEC, and Baker Hughes will mail the ...
Transcript: 2024 BOB IGER SHAREHOLDER VIDEO ; I’m Bob Iger – CEO of The Walt Disney Company. ; Ahead of our upcoming Annual Meeting, I wanted to update you about the Company’s significant recent achievements, and share why your vote this year is so important to Disney’s future.
0000950157-24-000203.txt : 20240213 0000950157-24-000203.hdr.sgml : 20240213 20240213172458 ACCESSION NUMBER: 0000950157-24-000203 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT...
By:, / s/ Joseph B. Armes, / s/ Joseph B. Armes ; Name:, Joseph B. Armes, Joseph B. Armes ; , Title:, Chairman of the Board
1., A copy of the Financial Institution Bond Standard Form No. 14, Bond No. FIB 0000609-11 in the amount of $900,000 (the “Fidelity Bond”); ; 2., A copy of the Secretary’s Certificate certifying the resolutions adopted by the Board of Directors, including all of the directors who are not interested persons, on July 21, 2008, approving the amount, type, form and coverage of the Fidelity Bond and including a statement as to the amount of the single insured bond that would have been obtained if the joint insured bond was not obtained and the period for which premiums for the Fidelity Bond have been paid; and ; 3., A copy of the agreement between the named insureds pursuant to Rule 17g-1(f).
Q1 2024 Update April 23rd, 2024 ; Table of Contents Key Highlights Financial Summary MAUs & Subscribers Product & Platform Outlook Financial Statements Executive Summary p.03 p.04 p.06 p.13 p.16 p.20 p.23 ; Executive Summary USER & FINANCIAL SUMMARY Q1 2023 Q4 2023 Q1 2024 Y/Y Q/Q USERS (M) Total Monthly Active Users ("MAUs") 515 602 615 19% 2% Premium Subscribers 210 236 239 14% 1% Ad-Supported MAUs 317 379 388 22% 2% FINANCIALS (€M) Premium 2,713 3,170 3,247 20% 2% Ad-Supported 329 501 389 1...
SECURITIES AND EXCHANGE COMMISSION · Washington, D.C. 20549 · FORM 8-K · CURRENT REPORT · PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 · Date of Report (Date of Earliest Event Reported) – January 11, 2006 · WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter)
UNITED STATES · SECURITIES AND EXCHANGE COMMISSION · WASHINGTON, D.C. 20549 · FORM 8-K · CURRENT REPORT · PURSUANT TO SECTION 13 OR 15(D) OF THE · SECURITIES EXCHANGE ACT OF 1934 · Date of Report (date of earliest event reported): June 9, 2021 · (Exact name of registrant as specified in its charter)